DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Nimotuzumab is an investigational drug.
There have been 67 clinical trials for Nimotuzumab. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2016.
The most common disease conditions in clinical trials are Carcinoma, Esophageal Neoplasms, and Carcinoma, Squamous Cell. The leading clinical trial sponsors are Biotech Pharmaceutical Co., Ltd., Peking University, and Chinese Academy of Medical Sciences.
There are fifty-nine US patents protecting this investigational drug and nine hundred and nine international patents.
Recent Clinical Trials for Nimotuzumab
|Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma||The First Affiliated Hospital of Zhengzhou University||Phase 2|
|Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma||Chinese Academy of Medical Sciences||Phase 2|
|Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma||Affiliated Cancer Hospital & Institute of Guangzhou Medical University||Phase 3|
Top disease conditions for Nimotuzumab
Top clinical trial sponsors for Nimotuzumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Nimotuzumab||Start Trial||Binding molecules specific for HER3 and uses thereof||MEDIMMUNE, LLC (Gaithersburg, MD)||Start Trial|
|Nimotuzumab||Start Trial||Multispecific constructs||AbbVie Stemcentrx LLC (North Chicago, IL)||Start Trial|
|Nimotuzumab||Start Trial||Anti-EGFR activatable antibodies||CytomX Therapeutics, Inc. (South San Francisco, CA)||Start Trial|
|Nimotuzumab||Start Trial||Substituted urea derivatives and pharmaceutical uses thereof||SUNSHINE LAKE PHARMA CO., LTD. (Dongguan, Guangdong, CN)||Start Trial|
|Nimotuzumab||Start Trial||Azabicyclo derivatives, process for preparation thereof and medical use thereof||Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (Shanghai, CN) Yangtze River Pharmaceutical Group Co., Ltd. (Jiangsu, CN)||Start Trial|
|Nimotuzumab||Start Trial||Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein||CureVac AG (Tubingen, DE)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|